130 related articles for article (PubMed ID: 31323075)
21. Prevalence of HIV infection and predictors of high-transmission sexual risk behaviors among men who have sex with men.
Schwarcz S; Scheer S; McFarland W; Katz M; Valleroy L; Chen S; Catania J
Am J Public Health; 2007 Jun; 97(6):1067-75. PubMed ID: 17463384
[TBL] [Abstract][Full Text] [Related]
22. Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed With Human Immunodeficiency Virus?
Koullias Y; Sax PE; Fields NF; Walensky RP; Hyle EP
Clin Infect Dis; 2017 Oct; 65(8):1274-1281. PubMed ID: 28605418
[TBL] [Abstract][Full Text] [Related]
23. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Raffi F; Rachlis A; Brinson C; Arasteh K; Górgolas M; Brennan C; Pappa K; Almond S; Granier C; Nichols WG; Cuffe RL; Eron J; Walmsley S
AIDS; 2015 Jan; 29(2):167-74. PubMed ID: 25387312
[TBL] [Abstract][Full Text] [Related]
24. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
[TBL] [Abstract][Full Text] [Related]
25. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness.
Stein JH; Ribaudo HJ; Hodis HN; Brown TT; Tran TT; Yan M; Brodell EL; Kelesidis T; McComsey GA; Dube MP; Murphy RL; Currier JS
AIDS; 2015 Sep; 29(14):1775-83. PubMed ID: 26372383
[TBL] [Abstract][Full Text] [Related]
26. Effect of antiretroviral therapy and viral load on the perceived risk of HIV transmission and the need for safer sexual practices.
Kravcik S; Victor G; Houston S; Sutherland D; Garber GE; Hawley-Foss N; Angel JB; Cameron DW
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Oct; 19(2):124-9. PubMed ID: 9768620
[TBL] [Abstract][Full Text] [Related]
27. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G
Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121
[TBL] [Abstract][Full Text] [Related]
28. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.
Jabłonowska E; Pulik P; Kalinowska A; Gąsiorowski J; Parczewski M; Bociąga-Jasik M; Pulik Ł; Siwak E; Wójcik K
J Med Virol; 2017 Dec; 89(12):2122-2129. PubMed ID: 28390164
[TBL] [Abstract][Full Text] [Related]
30. Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV.
Mahale PR; Patel BS; Kasmani N
Cureus; 2023 Jun; 15(6):e40139. PubMed ID: 37435267
[TBL] [Abstract][Full Text] [Related]
31. Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
Huhn GD; Sigman A; Livak B
Antivir Ther; 2015; 20(8):849-54. PubMed ID: 25881614
[TBL] [Abstract][Full Text] [Related]
32. Virologic Outcomes Among People Living With Human Immunodeficiency Virus With High Pretherapy Viral Load Burden Initiating on Common Core Agents.
Mills AM; Schulman KL; Fusco JS; Wohlfeiler MB; Priest JL; Oglesby A; Brunet L; Lackey PC; Fusco GP
Open Forum Infect Dis; 2021 Aug; 8(8):ofab363. PubMed ID: 34381843
[TBL] [Abstract][Full Text] [Related]
33. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
Taramasso L; Tatarelli P; Ricci E; Madeddu G; Menzaghi B; Squillace N; De Socio GV; Martinelli C; Gulminetti R; Maggi P; Orofino G; Vichi F; Di Biagio A; Bonfanti P;
BMC Infect Dis; 2018 Jul; 18(1):357. PubMed ID: 30064371
[TBL] [Abstract][Full Text] [Related]
34. Antiretroviral therapy and liver disorders in the OPERA
Wohlfeiler M; Mounzer K; Brunet L; Fusco J; Vannappagari V; Curtis L; Payvandi N; Aboud M; Hsu R; Lackey P; Fusco G
Ther Adv Drug Saf; 2020; 11():2042098620976953. PubMed ID: 33343858
[TBL] [Abstract][Full Text] [Related]
35. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
36. Might dolutegravir be part of a functional cure for HIV?
Wainberg MA; Han YS; Mesplède T
Can J Microbiol; 2016 May; 62(5):375-82. PubMed ID: 27031127
[TBL] [Abstract][Full Text] [Related]
37. Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database.
Hsu R; Fusco J; Henegar C; Mounzer K; Wohlfeiler M; Vannappagari V; Aboud M; Curtis L; Fusco G
Ther Adv Drug Saf; 2018 Dec; 9(12):675-686. PubMed ID: 30546862
[TBL] [Abstract][Full Text] [Related]
38. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
39. Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada.
Despiégel N; Anger D; Martin M; Monga N; Cui Q; Rocchi A; Pulgar S; Gilchrist K; Refoios Camejo R
Infect Dis Ther; 2015 Sep; 4(3):337-53. PubMed ID: 26099626
[TBL] [Abstract][Full Text] [Related]
40. Anogenital HIV RNA in Thai men who have sex with men in Bangkok during acute HIV infection and after randomization to standard vs. intensified antiretroviral regimens.
Phanuphak N; Teeratakulpisarn N; van Griensven F; Chomchey N; Pinyakorn S; Fletcher JL; Trichavaroj R; Pattanachaiwit S; Michael N; Phanuphak P; Kim JH; Ananworanich J;
J Int AIDS Soc; 2015; 18(1):19470. PubMed ID: 25956171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
